Compare · ABT vs ACRV
ABT vs ACRV
Side-by-side comparison of Abbott Laboratories (ABT) and Acrivon Therapeutics Inc. (ACRV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and ACRV operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $181.14B, about 2401.6x ACRV ($75.4M).
- ABT has been more active in the news (13 items in the past 4 weeks vs 1 for ACRV).
- ABT has more recent analyst coverage (25 ratings vs 11 for ACRV).
- Company
- Abbott Laboratories
- Acrivon Therapeutics Inc.
- Price
- -
- -
- Market cap
- $181.14B
- $75.4M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2022
- News (4w)
- 13
- 1
- Recent ratings
- 25
- 11
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- Abbott introduces Ensure® Max Protein 3-in-1 Muscle Support, bringing the benefits of a supplement stack into one scoop
- Barclays initiated coverage on Abbott Labs with a new price target
- Abbott receives FDA approval for new CardioMEMS HF System capabilities that help patients engage in the care of their heart condition
- SEC Form 4 filed by Director Stratton John G
- SEC Form 4 filed by Director Gonzalez Patricia Paola
- SEC Form 4 filed by Director Conroy Kevin T
- SEC Form 4 filed by Director Ahuja Nita
- SEC Form 4 filed by Director Roman Michael F
- Abbott Labs upgraded by Rothschild & Co Redburn with a new price target
- Abbott hosts conference call for third-quarter earnings
Latest ACRV
- SEC Form 4 filed by Acrivon Therapeutics Inc.
- Chief Business Officer Levin Michaela was granted 30,000 shares (SEC Form 4)
- SEC Form 3 filed by new insider Levin Michaela
- Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference
- Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer
- President and CEO Blume-Jensen Peter sold $30,969 worth of shares (14,036 units at $2.21) (SEC Form 4) to satisfy withholding obligation
- Chief Legal Officer Miller Mary sold $372 worth of shares (185 units at $2.01), decreasing direct ownership by 0.23% to 82,009 units (SEC Form 4) (withholding tax)
- Chief Accounting Officer Peterson Katharine sold $203 worth of shares (101 units at $2.01), decreasing direct ownership by 0.56% to 18,033 units (SEC Form 4) (tax liability)
- Chief Development Officer Gamelin Erick sold $804 worth of shares (400 units at $2.01), decreasing direct ownership by 0.75% to 52,592 units (SEC Form 4) (for tax liability)
- Chief Operating Officer Devroe Eric sold $1,214 worth of shares (604 units at $2.01), decreasing direct ownership by 0.41% to 146,349 units (SEC Form 4) (for tax liability)